The fragile X mutation can now be recognised by a variety of molecular techniques. We report a pilot screening survey of a population of children with mental impairment in which we used Southern blotting methods to detect the fragile X mutation, augmented by cytogenetic studies on children whose phenotype suggested a possible chromosome abnormality. There were 873 children with special educational needs in our survey and 310 fulfilled our criteria for testing. A sample was obtained from 254, of whom four were found to have a full fra(X) mutation (AL) and none to have a premutation.
Abstract
The fragile X mutation can now be recognised by a variety of molecular techniques. We report a pilot screening survey of a population of children with mental impairment in which we used Southern blotting methods to detect the fragile X mutation, augmented by cytogenetic studies on children whose phenotype suggested a possible chromosome abnormality. There were 873 children with special educational needs in our survey and 310 fulfilled our criteria for testing. A sample was obtained from 254, of whom four were found to have a full fra(X) mutation (AL) and none to have a premutation.
The number of CGG repeats in our population of X chromosomes was measured by PCR analysis and the genotype at the closely linked polymorphic locus FRAXAC1 established. The distribution of CGG repeat numbers was very similar to that of the control population reported by Fu et a) and the distribution of FRAXACI alleles almost identical to that of the control population reported by Richards et al. Among the non-fragile X chromosomes, we found a very significant correlation between the size of the CGG repeat and the FRAXACI genotype. There was a dearth of A and D genotypes in subjects with a small number of CGG repeats and an excess of the A genotype in those with a large number of CGG repeats. These observations are considered in the light of the reported disequilibrium between the A (and possibly also the D) genotype and the fra(X) mutation.
(J Med Genet 1993;30: Fragile X is the commonest inherited form of mental retardation with a prevalence of about 1 in 2000 males and 1 in 4000 females. 1 The fra(X) mutation is associated with a cytogenetically detectable fragile site, after which the syndrome is named. The fragile site is only seen when the cells of affected subjects are grown under conditions of thymidine perturbation. The cytogenetic marker is a good test for retarded males and most, but not all, retarded females; however, it fails to detect a proportion of retarded females and virtually all non-retarded carriers of both sexes. In spite of these disadvantages, until the advent of molecular diagnosis, the cytogenetic detection of the fragile site at Xq27.3 was the only test for the syndrome.
Recent research has shown that the fra(X) mutation results from expansion of a CGG repeat in the 5 The purpose of our study was fivefold: (1) to ascertain the efficacy of Southern blot analyses for population screening; (2) to ascertain the number of affected subjects (AL) detected by this technique; (3) to determine the number of CGG repeats on the X chromosomes by PCR technology from which the number of premutations may be inferred; (4) to determine the distribution of the FRAXACI polymorphism in our population; and (5) to determine the relationship between the FRAXAC1 genotype and the number of CGG repeats in our population of X chromosomes. We originally set out to determine the distribution of haplotypes at the fra(X) site by typing the bracketing polymorphisms FRAXAC1 and FRAXAC2; unfortunately, in our hands, the FRAXAC2 marker could not be typed reliably. However, as FRAXAC1 and FRAXAC2 are in strong 
Materials and methods

THE STUDY POPULATION AND SURVEY PROCEDURES
The study population consisted of children aged 5 to 18 years with SEN attending schools in the Salisbury and Isle of Wight Health Authority areas. The community health records from this group were reviewed and any who had documented medical reasons for their special needs (for example, Down's syndrome, cerebral palsy) were discarded. Those selected for testing were children for whom special educational provision was required, predominantly because of intellectual disability, and in whom no medical diagnosis for their special needs was noted. Details of the study population are given in tables 2 and 3.
A letter was sent to the parents of the children selected for testing giving a short explanation of fragile X and requesting permission to give their child a brief physical examination and take a sample of venous blood. A form to sign and a stamped addressed envelope were enclosed for their reply. If no reply was received from the parents after two weeks, a reminder was sent.
Children were seen in their schools as this caused minimum disruption and only involved the parents if they wished to be present. A brief clinical examination without undressing the child was carried out before each child was bled. The face, ears, palate, teeth, and hands were examined and any unusual features noted. Head circumference and ear length were measured. A 5 to 10 ml sample of blood was taken into EDTA in all cases and, if a chromosome anomaly was suspected on clinical grounds, a sample was also taken into lithium heparin.
If the results were normal the parents were informed by letter. If fragile X or a chromosome abnormality was found, a clinical geneticist contacted the parents directly. A repeat sample was taken by DNA and chromosome testing from each subject who had an abnormal result. When the result was confirmed the family was seen by a clinical geneticist and blood obtained from other appropriate family members. The family doctors were informed of the result in all cases. The CA repeat marker FRAXACI was studied using the protocols described by Richards et alP4 but with standard PCR buffer (Promega) and 2 pmol of one primer end labelled with y-[32P]dATP using T4 polynucleotide kinase (Cambio).
Results
A total of 310 children was selected for screening for the fragile X. However, 14 of these families could not be contacted and thus the study population consisted of 296 children. Of these, 257 (87%) agreed to the testing and a blood sample was obtained from 254 (86% whom is a mentally retarded brother with a AL; the mother who also has a AL is intellectually normal. One fra(X) proband's family was living abroad and no further studies have yet been done. table  6 and compared with that expected if CGG size and FRAXAC1 were segregating independently. As can be seen, there is a highly significant deviation between observed and expected (X24=45-1, p<0-001), with an absence of A and a reduction of D alleles in class 1 and a very marked excess of the A allele and a reduction in the numbers of C alleles in class 3. Sixteen females in our study had one X chromosome in which the number of CGG repeats was > 34 and 10 had an A allele at the FRAXACI locus, many more than expected by chance. 
Discussion
Our survey was clearly found to be acceptable both to the parents and teachers of the SEN children. We identified 873 SEN children in a population of 35 675 (2-4%) and detected four fra(X) males among the 180 tested and no fra(X) females among the 74 tested. Thus among the total population of 873 SEN children only four (0 5%) were fra(X) positive. This figure is considerably lower than that of Turner et aF who screened a total of 14 225 intellectually handicapped subjects of all ages in a population of 1-2 million (0-18%) and identified 253 (1-8%) fra(X) patients. As Turner et aF screened a much smaller proportion of their population, their sample must have been more rigorously selected than ours and presumably relatively enriched for fra(X) subjects. In our survey none of the fra(X) children would have been missed and only 102 children (40%) would have been bled if we had only taken blood when head circumference and ear length were above the 50th centile for age. These two measurements are known to be increased in fra(X) children and Turner (personal communication) has shown that they can be used to make screening more selective with little or no reduction in detection of fra(X) subjects. If we assume that in both this survey and that of Turner et al all mentally impaired fra(X) were detected, we have a population frequency of 4 in 35 675 or 1 in approximately 9000 while Turner et all have a population frequency of 253 in 1 2 million or 1 in 5000. These are of course very minimal estimates and Turner et all found the prevalence rates among children in the public school system to be 1 in 2610 males and 1 in 4221 females.
No expansion that clearly fell into the premutation size range was detected among the 309 independent X chromosomes tested. Eleven were in the range 41 to 49, the expansion potential of which is at present unknown, although unstable alleles have been described with repeat numbers as low as 43.9 We have been unable to follow the pattern of inheritance of these larger normal alleles, as that was not part of our original protocol.
The distribution of normal allele size among the X chromosomes in our population is very similar to that published by Fu et aP for 492 alleles obtained from three normal populations, namely mothers in CEPH families, blood donors from Texas, and normal spouses in North American fra(X) families. They, like us, have a major peak between 28 and 31 with approximately 30% of their X chromosomes having 29 repeats and a bimodal minor peak between 19 and 23. We appear to have a slightly wider spread with more alleles with 20 with the smallest number of repeats and an excess of the A allele among those chromosomes with the largest number of CGG repeats. This suggests that the number of CGG repeats on normal chromosomes may be related to their probability of expansion to premutation and full fragile X mutations. Indeed it has been shown'2 that the probability of mutation in a microsatellite increases with the copy number. However, it is not clear whether the copy number is the only determinant of expansion of the trinucleotide repeat or whether other factors play a role.
One might suppose (1) that the A allele of FRAXAC1 is associated with a factor which predisposes to CGG expansion, or (2) that the C allele is associated with a factor which protects against CGG expansion, or (3) that a factor predisposing to CGG expansion is a single, or one of a very few mutations which occurred by chance on a less common background haplotype, that is, a 'founder' mutation. Resolution of this issue might be possible with the analysis of other closely linked polymorphisms in the region of fragile X, a comparison of the expansion potential of similar sized CGG alleles of different genotypes, or perhaps from DNA sequence data.
Clearly, there is still much to be learned about the origin of the fragile X mutation and it will need extensive population studies and possibly some quite complex models to account for all the accumulated observations. However, a substantial benefit to patients and their families will be gained if, through these studies, a consistent correlation can be found between the risk of fragile X, size of the CGG repeat, and genetic background. At present the 'premutation' class of allele can only be defined either empirically, by its observed progression over several generations to a full mutation or arbitrarily, by creating an artificial threshold of presumed 'stability'. An important part of future screening surveys will be to investigate the families of all subjects with higher than average numbers of repeats and to assess the stability of such borderline expansions through meiosis, while relating this to their haplotypes for linked markers. Thus it may eventually become possible to define the premutation state more rigorously in a single person.
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